Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit variable serologic response to the vaccine. The capacity of vaccine-induced antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Nooka, Ajay K., Shanmugasundaram, Uma, Cheedarla, Narayana, Verkerke, Hans, Edara, Venkata V., Valanparambil, Rajesh, Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Lonial, Sagar, Azeem, Maryam, Manalo, Julia, Switchenko, Jeffrey M., Chang, Andres, Linderman, Susanne L., Roback, John D., Dhodapkar, Kavita M., Ahmed, Rafi, Suthar, Mehul S., Neish, Andrew S., Dhodapkar, Madhav V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462534/
https://www.ncbi.nlm.nih.gov/pubmed/35259002
http://dx.doi.org/10.1200/JCO.21.02257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462534/
https://www.ncbi.nlm.nih.gov/pubmed/35259002
http://dx.doi.org/10.1200/JCO.21.02257

Ejemplares similares